miR-410 suppresses the expression of interleukin-6 as well as renal fibrosis in the pathogenesis of lupus nephritis

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 6, 2016, Pages 616-625

  Liu, Dongmei ^a   Zhang, Na ^a   Zhang, Jing ^a   Zhao, Haiyan ^a   Wang, Xiaofei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Fibrosis; Interleukin 6 (IL 6); Lupus nephritis (LN); MiR 410; MRL lpr; SV40MES13

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; INTERLEUKIN 6; MICRORNA; MICRORNA 410; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; MIRN410 MICRORNA, MOUSE; PROTEIN BINDING;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; LUCIFERASE ASSAY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; FEMALE; FIBROSIS; GENE EXPRESSION; KIDNEY; MESANGIUM CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; FEMALE; FIBROSIS; GENE EXPRESSION; INTERLEUKIN-6; KIDNEY; LUPUS NEPHRITIS; MESANGIAL CELLS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MICRORNAS; PROTEIN BINDING;

EID: 84964857703     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12576     Document Type: Article

References (47)

1. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun. Rev. 2012; 12: 174-94.
2. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet 2007; 369: 587-96.
3. Tachaudomdach C, Kantachuvesiri S, Wongpraphairot S et al. High collagen I gene expression as an independent predictor of adverse renal outcomes in lupus nephritis patients with preserved renal function. Arch. Pathol. Lab. Med. 2015; 139: 378-87.
4. Garcia-Sanchez O, Lopez-Hernandez FJ, Lopez-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 2010; 77: 950-5.
5. Rahman A, Isenberg DA. Systemic lupus erythematosus. N. Engl. J. Med. 2008; 358: 929-39.
6. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 2013; 14: 475-88.
7. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 2008; 9: 102-14.
8. Xu J, Li Y, Wang F et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2013; 32: 976-87.
9. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv. Exp. Med. Biol. 2013; 774: 1-20.
10. Maes OC, Chertkow HM, Wang E, Schipper HM. MicroRNA: implications for Alzheimer disease and other human CNS disorders. Curr. Genomics 2009; 10: 154-68.
11. Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013; 382: 809-18.
12. Liu D, Zhao H, Zhao S, Wang X. MicroRNA expression profiles of peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Acta Histochem. 2014; 116: 891-7.
13. Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 2005; 64: 849-53.
14. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-43.
15. Eitner F, Westerhuis R, Burg M et al. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int. 1997; 51: 69-78.
16. Chun HY, Chung JW, Kim HA et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007; 27: 461-6.
17. Cui YX, Fu CW, Jiang F, Ye LX, Meng W. Association of the interleukin-6 polymorphisms with systemic lupus erythematosus: a meta-analysis. Lupus 2015; 24: 1308-17.
18. Qu B, Shen N. miRNAs in the pathogenesis of systemic lupus erythematosus. Int. J. Mol. Sci. 2015; 16: 9557-72.
19. Clay CC, Maniar-Hew K, Gerriets JE et al. Early life ozone exposure results in dysregulated innate immune function and altered microRNA expression in airway epithelium. PLoS ONE 2014; 9: e90401.
20. Peairs A, Dai R, Gan L et al. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell. Mol. Immunol. 2010; 7: 123-32.
21. Chung AC, Lan HY. MicroRNAs in renal fibrosis. Front. Physiol. 2015; 6: 50.
22. Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl. Res. 2010; 155: 109-17.
23. Cigni A, Pileri PV, Faedda R et al. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor alpha in active and quiescent systemic lupus erythematosus. J. Investig. Med. 2014; 62: 825-9.
24. Roderburg C, Luedde M, Vargas Cardenas D et al. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J. Hepatol. 2013; 58: 736-42.
25. Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. BioMed. Res. Int. 2014; 2014: 527895.
26. Chen L, Zhang J, Feng Y et al. MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int. J. Biochem. Cell Biol. 2012; 44: 1711-7.
27. Fukatsu A, Matsuo S, Yuzawa Y, Miyai H, Futenma A, Kato K. Expression of interleukin 6 and major histocompatibility complex molecules in tubular epithelial cells of diseased human kidneys. Lab. Invest. 1993; 69: 58-67.
28. Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T. Distribution of interleukin-6 in normal and diseased human kidney. Lab. Invest. 1991; 65: 61-6.
29. Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015; 76: 280-7.
30. Takemura T, Yoshioka K, Murakami K et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 1994; 424: 459-64.
31. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119: 296-305.
32. Tang B, Matsuda T, Akira S et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int. Immunol. 1991; 3: 273-8.
33. Sato S, Lennard Richard M, Brandon D et al. A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression. Arthritis Rheumatol. 2014; 66: 3436-44.
34. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004; 18: 816-27.
35. Wang B, Komers R, Carew R et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 2012; 23: 252-65.
36. Frenk J, Garnica ME, Zambrana M, Bronfman M, Bobadilla JL. [Migration and health: notes on an interdisciplinary field of research]. Salud Publica Mex. 1987; 29: 276-87.
37. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 2010; 21: 1317-25.
38. Lesk AM. Molecular biology. Coordination of sequence data. Nature 1985; 314: 318-9.
39. Wang B, Koh P, Winbanks C et al. miR-200a prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes 2011; 60: 280-7.
40. Liu Z, Yi J, Ye R et al. miR-144 regulates transforming growth factor-beta1 iduced hepatic stellate cell activation in human fibrotic liver. Int. J. Clin. Exp. Pathol. 2015; 8: 3994-4000.
41. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000; 85: 207-14.
42. Shahar I, Fireman E, Topilsky M et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin. Immunol. Immunopathol. 1996; 79: 244-51.
43. Fries KM, Felch ME, Phipps RP. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am. J. Respir. Cell Mol. Biol. 1994; 11: 552-60.
44. Le TT, Karmouty-Quintana H, Melicoff E et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J. Immunol. 2014; 193: 3755-68.
45. Park JI, Lee MG, Cho K et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 2003; 22: 4314-32.
46. Choi I, Kang HS, Yang Y, Pyun KH. IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clin. Exp. Immunol. 1994; 95: 530-5.
47. Wellmann U, Letz M, Schneider A, Amann K, Winkler TH. An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1 mice. Int. Immunol. 2001; 13: 1461-9.